NovoCure
NVCR
NVCR
265 hedge funds and large institutions have $3.78B invested in NovoCure in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 79 increasing their positions, 96 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
30% less capital invested
Capital invested by funds: $5.38B → $3.78B (-$1.6B)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 58
Holders
265
Holding in Top 10
2
Calls
$103M
Puts
$43.8M
Top Buyers
| 1 | +$48.1M | |
| 2 | +$36.8M | |
| 3 | +$22.6M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$21.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$20.8M |
Top Sellers
| 1 | -$109M | |
| 2 | -$12.6M | |
| 3 | -$9.48M | |
| 4 |
BlackRock
New York
|
-$8.46M |
| 5 |
JPMorgan Chase & Co
New York
|
-$7.96M |